

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
CLARKSBURG DIVISION**

REGENERON PHARMACEUTICALS, INC.,

Plaintiff,

v.

CELLTRION, INC.,

Defendant.

Case No. 1:23-cv-00089-TSK

JURY TRIAL DEMANDED

REGENERON PHARMACEUTICALS, INC.,

Plaintiff,

v.

SAMSUNG BIOEPIS CO., LTD.,

Defendant.

Case No. 1:23-cv-00094-TSK

JURY TRIAL DEMANDED

REGENERON PHARMACEUTICALS, INC.,

Plaintiff,

v.

FORMYCON AG,

Defendant.

Case No. 1:23-cv-00097-TSK

JURY TRIAL DEMANDED

**DECLARATION OF ANDREW E. GOLDSMITH IN SUPPORT OF
PLAINTIFF'S MOTION FOR ALTERNATIVE SERVICE**

I, Andrew E, Goldsmith, hereby declare as follows:

1. I am a partner at the law firm of Kellogg, Hansen, Todd, Figel & Frederick, P.L.L.C., counsel for Regeneron Pharmaceuticals, Inc. ("Regeneron") in the above-captioned

cases. I have appeared *pro hac vice* in these matters and am a member in good standing of the Bar of the State of New York and the Bar of the District of Columbia. I submit this Declaration in support of Regeneron's Motion for Alternative Service filed contemporaneously herewith. I have personal knowledge of the facts stated in this Declaration and am competent to testify to the same.

2. Attached hereto as Exhibit A is a true and correct copy of an email from Aviv Zalcnstein of Gemini Law, LLP ("Gemini"), counsel for Celltrion, Inc. ("Celltrion"), to Priyata Patel of Weil, Gotshal & Manges LLP ("Weil"), counsel for Regeneron, dated November 13, 2023.

3. Attached hereto as Exhibit B is a true and correct copy of an email sent by Shaun Van Horn of Jenner & Block LLP ("Jenner & Block"), counsel for Formycon AG, to Andrew Trask of Williams & Connolly LLP ("Williams & Connolly"), counsel for Regeneron, dated December 12, 2023.

4. Attached hereto as Exhibit C is a true and correct copy of an email sent by Shaun Van Horn of Jenner & Block to Tom Fletcher of Williams & Connolly, dated November 10, 2023.

I, Andrew E. Goldsmith, declare under penalty of perjury that the foregoing is true and correct.

Dated: December 22, 2023

/s/ Andrew E. Goldsmith
Andrew E. Goldsmith